市場調查報告書

生長激素市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年

Somatropin Market, By Dosage Form, By Application, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952875
出版日期 內容資訊 英文 201 Pages
商品交期: 2-3個工作天內
價格
生長激素市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年 Somatropin Market, By Dosage Form, By Application, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年08月04日內容資訊: 英文 201 Pages
簡介

根據2019年7月International Journal of Molecular Sciences刊載的記事,生長激素缺乏症,是創傷性腦損傷的長期生存者中最常見的荷爾蒙缺乏症。由於創傷性腦損傷的生長激素缺乏症的患病人數增加,預計在預測期間內促進全球生長激素市場成長。

本報告提供全球生長激素市場相關調查分析,市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的與前提條件

第2章 市場範圍

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的發展
  • PEST分析

第4章 全球生長激素市場 - COVID-19大流行疫情的影響

  • 影響評估
  • COVID-19前的市場方案
  • COVID-19後的市場方案
  • 對抗COVID-19的政府對策

第1章 全球生長激素市場:各劑型

  • 簡介
  • 粉末
  • 溶媒

第2章 全球生長激素市場:各適應症

  • 簡介
  • 生長激素缺乏症(GHD)
  • 透納氏症
  • 慢性腎衰竭
  • 普拉達威利症候群
  • 胎兒小於妊娠年齡 (SGA)
  • SHOX缺乏症
  • 其他

第3章 全球生長激素市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第4章 全球生長激素市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第5章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Novo Nordisk A/S
    • Device Portfolio
    • Pfizer, Inc.
    • Device Portfolio
    • Eli Lilly and Company
    • Device Portfolio
    • GeneScience Pharmaceuticals
    • Device Portfolio
    • Sandoz International
    • Device Portfolio
    • Ipsen Inc.
    • Device Portfolio
    • LG Life Sciences
    • Device Portfolio
    • Merck KGaA
    • Device Portfolio
    • F. Hoffmann-La Roche
    • Device Portfolio
    • Teva Pharmaceutical Industries Ltd.
    • Device Portfolio
    • Ferring Pharmaceuticals
    • Device Portfolio
  • 分析師的見解

第6章 Section

目錄

The increasing prevalence of growth hormone deficiency due to traumatic brain injuries is expected to propel the growth of the global somatropin market during the forecast period. According to an article published in the International Journal of Molecular Sciences in July 2019, growth hormone deficiency is the most common hormone deficiency in long term survivors of traumatic brain injury.

Market Dynamics

Market players are focusing on adopting various inorganic growth strategies such as agreements and acquisitions to strengthen their market presence and enhance their product portfolio. This is expected to drive growth of the global somatropin market during the forecast period. For instance, in October 2017, Ferring Pharmaceuticals entered a definitive agreement with Antares Pharma, Inc. to acquire the rights for the ZomaJet needle-free auto injector device.

Furthermore, research and development activities by key players are expected to propel the growth of global somatropin market during the forecast period. For instance, March 2017, GeneScience Pharmaceuticals Co., Ltd. initiated a phase 4 clinical trial to evaluate the safety and efficacy of PEG-Somatropin for the treatment of pediatric patients with growth hormone deficiency.

Key features of the study:

  • This report provides in-depth analysis of the global somatropin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global somatropin market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, Sandoz International, Ipsen Inc., LG Life Sciences, Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, market expansion, and marketing tactics
  • The global somatropin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global somatropin market.

Detailed Segmentation:

  • Global Somatropin Market, By Dosage Form:
    • Powder
    • Solvent
  • Global Somatropin Market, By Application:
    • Growth Hormone Deficiency (GHD)
    • Turner Syndrome
    • Chronic Renal Insufficiency
    • Prader Willi Syndrome
    • Small for Gestational Age
    • SHOX Deficiency
    • Others
  • Global Somatropin Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Somatropin Market, By Region:
    • North America
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Dosage Form:
      • Powder
      • Solvent
      • By Application
      • Growth Hormone Deficiency (GHD)
      • Turner Syndrome
      • Chronic Renal Insufficiency
      • Prader Willi Syndrome
      • Small for Gestational Age
      • SHOX Deficiency
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Novo Nordisk A/S*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Eli Lilly and Company
    • GeneScience Pharmaceuticals
    • Sandoz International
    • Ipsen Inc.
    • LG Life Sciences
    • Merck KGaA
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries Ltd.
    • Ferring Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Dosage Form
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Somatropin Market - Impact of Coronavirus (Covid-19) Pandemic

  • Impact assessment
  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Government measures to combat COVID-19

1. Global Somatropin Market, By Dosage Form, 2016 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Powder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Solvent
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

2. Global Somatropin Market, By Application, 2016 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Growth Hormone Deficiency (GHD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Turner Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Chronic Renal Insufficiency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Prader Willi Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Small for Gestational Age
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • SHOX Deficiency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

3. Global Somatropin Market, By Distribution Channel, 2016 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

4. Global Somatropin Market, By Region, 2016 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Dosage Form, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Bn)
    • South Africa
    • Central Africa
    • North Africa

5. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Novo Nordisk A/S
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GeneScience Pharmaceuticals
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sandoz International
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ipsen Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • LG Life Sciences
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck KGaA
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • F. Hoffmann-La Roche
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ferring Pharmaceuticals
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

6. Section

  • References
  • Research Methodology
  • About us and Sales Contact